Rocket Pharmaceuticals, Inc. $RCKT

What the company doesAI summary of filing

Rocket Pharmaceuticals is a clinical-stage biopharmaceutical company developing gene therapy treatments using adeno-associated virus (AAV) and lentiviral vector technologies for rare genetic diseases and certain cardiomyopathies. The company's pipeline includes candidates targeting conditions such as Leukocyte Adhesion Deficiency-I, Fanconi Anemia, Pyruvate Kinase Deficiency, Danon Disease, and arrhythmogenic cardiomyopathy. Rocket is pursuing regulatory approvals from the FDA and other authorities and does not currently generate revenue from product sales. The company funds its operations through equity offerings and private placements while advancing its drug candidates through clinical development stages. [10-K 2026-02-26]

Segments: AAV gene therapy programs, Lentiviral vector programs, Cardiomyopathy programs, Rare genetic disease programs